WFTV’s Greg Warmoth Joins AdventHealth’s Dr. Mark Socinski to Discuss His Cancer Journey — and How He Hopes His Message Will Save Others

Side by side headshots of Greg Warmoth and Mark Socinski
Greg Warmoth, WFTV anchor (left) and Dr. Mark Socinski, AdventHealth Cancer Institute executive medical director (right)

Greg Warmoth, long-time WFTV anchor, shares his journey with lip cancer — a tale of caution and hope — in this episode of AdventHealth’s Inspiring Wholeness podcast. He’s joined by Dr. Mark Socinski, executive medical director of the AdventHealth Cancer Institute.

“My mission is to tell people to get checked,” Warmoth says. “The odds are good. It may be nothing, but if it is, it can be fixed. You can be healed. You can move on.”

Listen now and subscribe so you never miss a new episode.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...

Read Article about "New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma"
News
AdventHealth for Children Recruiting Patients with Fabry Disease for Phase III PERIDOT Clinical Trial Evaluating a Potential New Treatment Option

Under the leadership of Medical Director of Genomics and Personalized Health Majed Dasouki, MD, AdventHealth for Children is recruiting patients for a new Phase III clinical trial to evaluate the...

Read Article about "AdventHealth for Children Recruiting Patients with Fabry Disease for Phase III PERIDOT Clinical Trial Evaluating a Potential New Treatment Option"
View More Articles